Sample size: While the study included 56 patients, a larger cohort may be necessary to generalize the findings across diverse populations and settings

The gap

Evidence profile

Sourced from the future work and limitations section of the source papers, classified as general, drawn from work published between 2025 and 2026, spanning 3 journals. Those papers have been cited 24 times in total.

Supporting evidence — 3 representative gaps

• High-altitude exposure and ischemic stroke: pathophysiological mechanisms and current perspectives (2026) · Frontiers in Neurology · doi

  6.1 Current limitations Despite considerable advances, several important limitations warrant emphasis. A standardized framework for high-altitude exposure modeling remains lacking, particularly with respect to altitude gradients, exposure duration, and methods of hypoxic stimulation. This variability introduces substantial methodological heterogeneity across studies, complicating direct comparisons. Although accumulating evidence supports a transition from physiological acclimatization to maladaptive injury, the precise mechanisms governing this shift—and the interactions among distinct pathological pathways—remain incompletely understood. Moreover, much of the extant literature derives from controlled experimental hypoxia models, which may not fully recapitulate the complexity of long-term cerebrovascular adaptation and injury in real-world high-altitude environments. Collectively, these constraints limit mechanistic interpretation and reduce the translational generalizability of current findings. 6.2 Clinical implications and management challenges Beyond unresolved mechanistic questions, several clinical salient challenges remain inadequately addressed in the context of high-altitude-associated ischemic stroke. Timely reperfusion therapy is paramount, as treatment delays are strongly correlated with poorer outcomes (206). In remote high altitude regions, logistical constraints—including limited healthcare infrastructure, suboptimal resource allocation, and inefficient workflows—can further delay definitive treatment (206, 207). Additionally, hypoxemia and excessive erythrocytosis, both characteristic of high-altitude physiology, may complicate clinical management and thrombotic risk stratification (208). Given the marked physiological heterogeneity among high-altitude populations, universally applicable management strategies remain undefined, and population-specific approaches are likely necessary (208). Prospective, high-quality studies are urgently needed to establish evidence-based clinical management strategies for ischemic stroke in these settings. 6.3 Future perspective Future research should prioritize several key directions. First, prospective studies that integrate clinical variables, advanced neuroimaging, circulating biomarkers, and machine learning-based analytics may refine risk stratification and facilitate individualized risk profiling for high-altitude-related ischemic stroke (209, 210). In alignment with this objective, our research group is conducting a multicenter prospective cohort study across the western Sichuan plateau (Chinese Clinical Trial Registry identifier: ChiCTR2400092762) aimed at developing prognostic prediction models based on clinical, neuroimaging, and multidimensional biological data (211). Third, Second, interventional should evaluate whether studies targeted therapies can sustain beneficial acclimatization while attenuate maladaptive responses during prolonged hypoxic exposure. Promising avenues include oxygen therapy (212, 213) and antioxidant strategies (214); however, their efficacy and optimal implementation in high-altitude-associated ischemic stroke remain to be rigorously established. altitude-specific and management frameworks require systematic evaluation. Particular emphasis should be placed on clinically actionable domains, including blood pressure control, hemoglobin modulation, antithrombotic therapy, and equitable access to reperfusion treatment (215, 216). Current evidence remains insufficient to endorse standardized management protocols applicable across heterogeneous high- altitude populations. Well-designed prospective trials are therefore to define evidence-based preventive and therapeutic essential paradigms for ischemic stroke in high-altitude environments. prevention

  generalfuture work
  Keywords: altitude high clinical management ischemic stroke evidence remain prospective based current several exposure across therapy
• Neuroprotective effects and mechanistic insights of sinomenine in ischemic stroke: a systematic review and meta-analysis of preclinical animal studies (2026) · Frontiers in Pharmacology · doi

  4.6.1 Discrepancies between administration time windows and clinical treatment contexts is generally restricted The translational relevance of this study is constrained by the uneven distribution of administration timing. Approximately 75% of the included studies employed pretreatment protocols, resulting in pooled effect sizes substantially influenced by pretreatment data. However, stroke onset is unpredictable, and the clinical use of neuroprotective agents the acute therapeutic window after stroke onset (Paul and Candelario-Jalil, 2021; Zhang et al., 2025). Pretreatment models assess biological effects under pharmacologically protected states established prior to ischemia, which does not accurately reflect the clinical scenario of initiating treatment after stroke. Therefore, current evidence is insufficient to directly infer the clinical efficacy of sinomenine in stroke patients or to support its extrapolation to acute-phase clinical application. to 4.6.2 Differences between animal model characteristics and clinical patient profiles The included studies predominantly used young, healthy male rodents, whereas clinical ischemic stroke populations are typically older and exhibit sex-related differences and comorbidities, including hypertension, diabetes, and obesity. Consequently, existing animal models are unable to adequately recapitulate the complex pathophysiological features of clinical stroke, thereby limiting the external validity of the research findings. Moreover, cerebral ischemia models differ substantially in their underlying mechanisms and the clinical stroke scenarios they represent (Matur et al., 2023; Mendes et al., 2026). All included studies employed the tMCAO model, without validation in permanent MCAO, photothrombotic, or embolic models, further restricting the generalizability of the evidence across diverse stroke subtypes. 4.6.3 Inadequate pharmacological characterization and safety data The included studies inadequately reported pharmacological information regarding sinomenine. Only one study reported drug purity, whereas the others provided no information on this parameter. Variability in drug quality may alter exposure to the active compound and its pharmacological effects, potentially the limiting to contributing reproducibility and clinical the findings. Moreover, none of the included studies reported safety outcomes, and all used short-term administration regimens. Consequently, the safety of sinomenine in the context of ischemic stroke cannot be evaluated, nor can the toxicological risks, maximum tolerated dose, or therapeutic window associated with long-term administration be determined. inter-study heterogeneity and translatability of 4.6.4 Inadequate adherence to ARRIVE 2.0 and STAIR guidelines The included studies exhibited deficiencies in experimental design, methodological reporting, and translational rigor. Based on the ARRIVE 2.0 Essential 10 items and STAIR guidelines, most studies inadequately reported key methodological parameters, including randomization procedures, blinding methods, and sample size calculations. Moreover, critical translational elements, such as therapeutic and multi-species validation, validation in aged animals, inclusion of female and comorbid animal models, and long-term functional outcome assessment, were insufficiently addressed. These shortcomings may compromise reproducibility and internal validity, thereby limiting the translational potential of sinomenine for clinical application. time windows, multi-model Future studies should comply with the ARRIVE 2.0 and STAIR guidelines, conduct standardized, multicenter, and independently replicated validations, and report negative and neutral results to reduce publication bias. Experimental designs should incorporate post-stroke dosing paradigms that better approximate clinical practice, systematically evaluate dose-response and time-response relationships across therapeutic windows, and establish safety pharmacology parameters and long-term functional outcomes as further standard observational endpoints. Validation should

  generalfuture work
  Keywords: clinical stroke included models administration translational therapeutic sinomenine validation safety reported term time windows pretreatment
• The Role of IL-6 and TNF-Alpha Biomarkers in Predicting Disability Outcomes in Acute Ischemic Stroke Patients (2025) · Life · cited 24× · doi

  Sample size: While the study included 56 patients, a larger cohort may be necessary to generalize the findings across diverse populations and settings - Timing of biomarker measurement: Biomarkers were measured only on days 1 and 7, which may miss important fluctuations in cytokine levels during the acute and subacute phases of stroke - Single-center study: The study was conducted at a single institution. This may limit the generalizability of the findings to other centers with different patient populations or clinical practices - Lack of long-term follow-up: The study may not account for the long-term evolution of inflammation and its effects on stroke recovery, focusing primarily on early poststroke outcomes - Exclusion of other biomarkers: The study focused on IL-6 and TNF-alpha, but there are other inflammatory and non-inflammatory markers that may also play a role in stroke prognosis, potentially limiting the scope of the analysis - Measurement techniques: Variations in the sensitivity or specificity of assays used to measure IL-6 and TNF-alpha might affect the reliability of biomarker levels - Heterogeneity in stroke severity: Patients with varying degrees of stroke…

  generallimitations sectionevidence 5/5
  Keywords: sample size study included patients larger cohort necessary

Questions about this gap